1.31

2.96% -0.04

After Hours: 1.31

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $1.31, with a volume of 546.96K. It is down -2.96% in the last 24 hours and down -18.13% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Previous Close:

$1.35

Open:

$1.35

24h Volume:

546.96K

Relative Volume:

0.30

Market Cap:

$246.14M

Revenue:

Net Income/Loss:

$-222.39M

P/E Ratio:

-0.9873

EPS:

-1.3268

Net Cash Flow:

$-193.40M

1W Performance:

-5.76%

1M Performance:

-18.13%

6M Performance:

-57.05%

1Y Performance:

-19.63%

1-Day Range:

$1.29

$1.36

1-Week Range:

$1.29

$1.445

52-Week Range:

$0.8302

$3.65

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(857) 760-0900

Address

260 ARSENAL PLACE, SUITE 1, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-08-19

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	1.31	284.66M	0	-222.39M	-193.40M	-1.3268
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-12-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Mar-07-25	Downgrade	Stifel	Buy → Hold
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Sep 06, 2026

NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits

Sep 06, 2026

Sep 04, 2026

BlackRock Inc. Buys Shares of 7,791,869 Neumora Therapeutics, Inc. $NMRA - MarketBeat

Sep 04, 2026

Aug 29, 2026

Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher - simplywall.st

Aug 29, 2026

Aug 25, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 25, 2026

Aug 24, 2026

2,559,090 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by ICONIQ Capital LLC - MarketBeat

Aug 24, 2026

Aug 22, 2026

Neumora Therapeutics COO Aurora disposes of $269,966 in stock - Investing.com India

Aug 22, 2026

Aug 21, 2026

Daljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat

Aug 21, 2026

Neumora Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Aug 21, 2026

Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo

Aug 21, 2026

Neumora Therapeutics (NMRA) grants chair 500K stock options - Stock Titan

Aug 21, 2026

Neumora Therapeutics (NASDAQ: NMRA) officer plans 41,608-share sale after August trades - Stock Titan

Aug 21, 2026

Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock By Investing.com - Investing.com South Africa

Aug 19, 2026

Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares - MarketBeat

Aug 19, 2026

Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 34,987 Shares - MarketBeat

Aug 19, 2026

Neumora Therapeutics (NMRA) insider plans new stock sale after $329K in recent trades - Stock Titan

Aug 19, 2026

Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst - MarketBeat

Aug 19, 2026

Neumora Therapeutics, Inc. Stock 12‑Month Price Target Raised to $6.67, Implies 307% Upside - TradingView

Aug 19, 2026

Aug 18, 2026

Neumora (NASDAQ: NMRA) insider to sell 69K more shares - Stock Titan

Aug 18, 2026